|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L01XE04
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Sutent
|
|
gptkbp:CASNumber
|
gptkb:557795-19-4
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to sunitinib
|
|
gptkbp:eliminationHalfLife
|
40-60 hours
|
|
gptkbp:hasDrugBankURL
|
https://go.drugbank.com/drugs/DB04951
|
|
gptkbp:hasInChIKey
|
PJNSMUBMSNAEEN-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H27FN4O2
|
|
gptkbp:hasSMILES
|
CC1=CC(=NC=C1NC2=CC(=C(C=C2)F)C(=O)NC3CCCCC3)C4=CN=CC=C4
|
|
gptkbp:hasUNII
|
UH2A2J35Y7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB04951
|
|
gptkbp:indication
|
gptkb:gastrointestinal_stromal_tumor
gptkb:pancreatic_neuroendocrine_tumors
renal cell carcinoma
|
|
gptkbp:legalStatus
|
expired (in some regions)
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
hepatic (CYP3A4)
|
|
gptkbp:molecularWeight
|
398.477
|
|
gptkbp:name
|
gptkb:Sunitinib
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
diarrhea
fatigue
hypertension
mucositis
|
|
gptkbp:bfsParent
|
gptkb:Esbriet
|
|
gptkbp:bfsLayer
|
7
|